The PGDx elio™ Plasma Focus Dx is a highly specific, sensitive, reproducible, and accurate hybrid capture-based next-generation sequencing (NGS) assay optimized for cell-free DNA with excellent performance in analytical validation studies across various variant types and solid tumor types.

The Labcorp Plasma Focus test demonstrated a 95.8% success rate and was able to detect clinically actionable variants across various cancer types, with rapid reporting for the majority of cases, highlighting its effectiveness in informing precision oncology decision-making.

The TSO500 HT assay has been effectively validated to genotype HLA-A, -B, and -C from tumor samples, providing valuable tumor-informed HLA allele haplotypes with high accuracy, which can aid clinicians and drug developers in selecting HLA-directed therapies and enrolling patients in HLA-restricted clinical trials across various tumor types, includ

The use of LAG-3 expression as a clinical biomarker to select for patients who might benefit from anti-LAG-3 immuniotherapies might require multiple rapid, sensitive, and accurate assays.

Non-V600 BRAF mutated melanomas, compared to those with BRAF V600 mutations or BRAF WT tumors, had higher levels of immune cell infiltration, increased tumor mutation burden (TMB), and elevated expression of immune checkpoint and T cell exhaustion markers, indicating a potentially favorable response to combination immune checkpoint inhibitors (ICP

This study developed and validated a workflow for accurately determining the genetically inferred ancestry (GIA) of patients from comprehensive genomic profiling (CGP) sequencing results, which can enable ancestry-aware biomarker research and contribute to reducing cancer disparities and improving representation in clinical trials.

Comprehensive genomic and immune profiling of invasive breast cancers, including a lobular-enriched cohort and non-lobular cohort, revealed that lobular-enriched tumors had distinct molecular and immunologic characteristics.

The study shows that tumor tissues collected in vivo had a higher tumor immunogenicity signature and lower cellular proliferation signature compared to cell lines grown in culture, indicating that an active immune system and a vascularized environment contribute to decreased cancer cell proliferation.

ALK-positive lung adenocarcinomas are associated with a younger age at sequencing, lower tumor mutational burden, higher PD-L1 expression, and lower cancer testis antigen burden compared to ALK-wild-type, EGFR mutated, and KRAS

Distinct genomic alterations were identified in different gene expression and immunotherapy marker defined immune-response phenotypes, with tumor-dominant phenotype tumors having the highest number of enriched alterations.